Using AI-driven models to predict metabolic instabilities in different diseases, ScandiBio develops therapies targeting metabolic and mitochondrial dysfunction.
Investors 1
| Date | Name | Website |
| - | Navigare V... | navigareve... |
Mentions in press and media 1
| Date | Title | Description |
| 04.11.2025 | ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease | ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease Tue, Nov 04, 2025 08:25 CET Report this content Alzheimer’s disease (AD) is the most common cause of dem... |